SRR17866825
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 49.2
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.530
- INTERFERON_GAMMA_RESPONSE+0.440
- ALLOGRAFT_REJECTION+0.410
- INTERFERON_ALPHA_RESPONSE+0.380
- COMPLEMENT+0.350
- UV_RESPONSE_DN+0.340
- BILE_ACID_METABOLISM+0.330
- PROTEIN_SECRETION+0.320
- INFLAMMATORY_RESPONSE+0.280
- ANDROGEN_RESPONSE+0.260
Top 10 suppressed
- MYC_TARGETS_V2-0.740
- MYC_TARGETS_V1-0.600
- E2F_TARGETS-0.500
- DNA_REPAIR-0.400
- G2M_CHECKPOINT-0.360
- OXIDATIVE_PHOSPHORYLATION-0.300
- WNT_BETA_CATENIN_SIGNALING-0.290
- MTORC1_SIGNALING-0.270
- NOTCH_SIGNALING-0.260
- TNFA_SIGNALING_VIA_NFKB-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12475115 | — | — | 0.881 |
| 2 | SRR12475112 | — | — | 0.874 |
| 3 | TCGA-91-7771-01A-11R-2170-07 | — | cohortA2 | 0.853 |
| 4 | SRR17866835 | — | — | 0.850 |
| 5 | SRR12475139 | — | — | 0.844 |
| 6 | BS_CTR5X93B | pilocytic astrocytoma | — | 0.832 |
| 7 | SRR12475121 | — | — | 0.831 |
| 8 | TCGA-97-7552-01A-11R-2039-07 | — | cohortA1 | 0.820 |
| 9 | TCGA-99-7458-01A-11R-2039-07 | — | cohortA1 | 0.814 |
| 10 | SRR8518405 | — | A | 0.809 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.530 | Cobimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.440 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.410 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.380 | Inavolisib | — uncovered |
| COMPLEMENT | 0.350 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.340 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.330 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.320 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.280 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.260 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.250 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.230 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.190 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.190 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.190 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.180 | Temsirolimus | — uncovered |
| TGF_BETA_SIGNALING | 0.180 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |